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ABSTRACT
BACKGROUND 
Increases in aminotransferases (transaminitis) are  potential ma-
jor adverse reactions seen with long-term use of methotrexate 
(MTX). The aim of this study, therefore was to evaluate the inci-
dence of MTX induced hepatotoxicity and its risk factors among 
rheumatoid arthritis (RA) patients.
METHODS 
This retrospective study described 286 patients with RA who 
received ≥ 7.5 mg MTX weekly in an academic rheumatology 
clinic over a  15 year period. The results of serial liver function 
tests, concurrent MTX dose, cumulative dose and use of  hepa-
totoxic drugs were collected and statistically analyzed according 
to a consecutive elevation  in aminotransferases which occurred  
over at least a two week interval.
RESULTS 
During the study period, 286 patients (84.4% female) with mean 
age of 46.6±12.7 years (18-84 years) were enrolled.  Transa-
minitis occurred among 23.7% of patients (incidence: 6.9 per 
100 person-years) during 40.5±34.6 month’s exposure to MTX 
(989.6 person-years). The time difference between onset of ther-
apy and occurrence of transaminitis was 22.1±22.0 months.
The only significant factor related to the occurrence of transami-
nitis was the duration of MTX therapy. The average duration of 
treatment among patients with transaminitis (59.6±42.3 months) 
was greater than those with no transaminitis (p<0.001). The cu-
mulative dose of MTX was significantly related to the occur-
rence of transaminitis (p<0.001).
CONCLUSION 
MTX hepatotoxicity is a common complication of long-term treat-
ment with MTX. It is associated with mild liver enzyme elevation and 
related to the duration of therapy.  
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INTRODUCTION
Methotrexate (MTX), as the most disease 
modifying anti-rheumatic drug used for rheu-
matoid arthritis (RA), has been available for 
clinical use since 1951.1 Its widespread avail-
ability along with the high prevalence of RA 
which requires long-term therapy has attracted 
physicians’ attention to the adverse reactions 
of MTX. The increases in aminotransferases 
(transaminitis) are a potential major adverse 
reaction seen with long-term use of MTX. 
Many risk factors such as age, duration of 
exposure to MTX and its cumulative dose, his-
tory of non alcoholic steatohepatitis (NASH), 
diabetes and obesity, hepatitis B or C virus in-
fection, alcohol consumption and hepatotoxic 
drugs can increase the hepatotoxic effect of 
MTX.2-11 
The incidence of MTX-induced transami-
nitis varies according to different definitions. 
Some papers10,12 have defined it as elevated 
liver enzymes 2-3 times greater than the nor-
mal range. These studies have estimated the 
frequency of transaminitis to be 7.5 to 26% 
of all patients treated with MTX. Others have 
histologically defined it as grades ІІІ B and 
ІV based on the Roenigk classification. In this 
group, the frequency varied from 1% by Kre-
mer et al.13 who analyzed pooled data from 17 
studies, 7.5% by Erickson et al.14 and as high 
as 27 or 29% in other studies.5,15 
In this retrospective study, the incidence of 
MTX induced transaminitis among RA patients 
and its risk factors are evaluated in a large re-
ferral university clinic.
MATERIALS AND METHODS
Data were obtained in three different question-
naires, which were completed by RA patients in 
an academic rheumatology clinic. Patients had 
received ≥7.5 mg MTX weekly for at least one 
month during their follow up from 1991-2006. 
Abnormal LFT was defined as above normal 
laboratory range.
Patients who used less than 7.5mg or with a  
duration of less than one month were exclud-
ed. In addition, patients were excluded from 
the study if their liver function tests (LFT) 
were checked once during the treatment period 
or positive hepatitis viral markers (HBs-Ag, 
HCV Antibody) were noted.
The first questionnaire was completed by pa-
tient interviews and chart reviews. This ques-
tionnaire consisted of primary data regarding 
age, gender, BMI, disease activity, alcohol 
consumption, cigarette smoking, presence of 
liver disease including fatty liver or non-alco-
holic steatohepatitis (NASH) and autoimmune 
hepatitis, presence of diabetes, dyslipidemia, 
renal failure and congestive heart failure and 
use of concurrent hepatotoxic drugs.
In the second questionnaire, documents of 
the patients’ charts of every visit date from 
1991 in addition to the concurrent weekly 
dose of MTX, its cumulative dose and results 
of serial laboratory tests (longitudinal course) 
which included complete blood cell counts 
(CBC), fasting blood sugar (FBS), lipid pro-
files, blood urea nitrogen (BUN), creatinine, 
aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase, 
serum albumin, prothrombin time and biliru-
bin were obtained. Moreover, if MTX was dis-
continued during the patient’s follow up, the  
cause for discontinuation was identified based 
on chart review.
Among patients with incidental abnormal 
liver function tests (LFT), further evaluations 
of HBs antigen, HCV antibody, liver sonogra-
phy and liver biopsies (if noted in the charts or 
as reported by the patients) were collected in 
the third questionnaire.
Finally the database that included 295 pa-
tients who received ≥7.5 mg MTX weekly for 
at least one month were prepared for analysis 
by SPSS. Reliable p-values by chi-square or 
T -test and Multi-variant analysis were gath-
ered. Other findings which included the time 
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of the first enzyme assay after onset of therapy, 
the time and intervals of LFT measurement 
throughout the treatment, creatinine clearance 
(Crcl), BMI and total cumulative dose of MTX 
were calculated.
In the presence of an abnormal LFT, the time 
of the enzyme assay, concurrent dose of MTX 
and concurrent cumulative dose, times of LFT 
abnormalities, presence of the abnormal liver 
enzyme level 2-3 times above the normal range 
and any change in the treatment strategy such 
as changes in MTX dose or intervals of LFTs 
and the level of the next consecutive enzyme 
(normal or high) were all evaluated. 
For better evaluation of MTX-induced trans-
aminitis and exclusion of incidental findings 
for abnormal enzymes (e.g., laboratory errors) 
and other causes of liver enzyme elevation, 
four categories were defined: 
1. Patients who had two consecutive enzyme 
elevations with at least a two week interval 
or those with synchronous changes in en-
zyme levels by MTX doses (decreased en-
zyme levels after reduced dose or discon-
tinuation) were defined as “definite cases 
of MTX-induced transaminitis” in the ab-
sence of any other absolute cause for LFT 
abnormalities.
2. Patients with at least two non-consecutive 
enzyme elevations without another expla-
nation for the elevation were assumed to 
be “probable cases of MTX-induced trans-
aminitis”.
3. Patients with only one abnormal LFT  
detected during the treatment period and 
subsequent normal levels of enzymes, with-
out any synchronous change in MTX dose, 
were categorized as “less probable cases of 
MTX-induced transaminitis”.
4. Patients who had other documented causes 
of LFT abnormalities such as autoimmune 
hepatitis, CHF and hepatic congestion, 
NASH and the use of other hepatotoxic 
drugs were assumed as “others”. 
In this classification, groups 1 and 2 were 
defined as MTX-induced transaminitis and 
used for risk factor evaluation.
In order to eliminate the significant treat-
ment duration effects on the total cumulative 
dose and for better evaluation of pure MTX 
dose effects on transaminitis, the proportion of 
cumulative dose (mg) to duration of therapy 
(months) was calculated in each group and de-
termined to be the total density of MTX dose 
per month.
RESULTS
Totally, 286 patients were treated with MTX 
for 40.5±34.6 months (range: 1-168 months; 
989.6 person-years exposure to MTX) with 
2567 LFT recorded and 177 (35.7%) ab-
normal tests. The mean LFT interval mea-
surement was 4.7±3.0 (0.7-30) months. 
Transaminitis occurred among 23.7% of pa-
tients (95% CI: 18.4-29.5). The incidence of 
transaminitis was 6.9 per 100 person-years  
exposure to MTX (95% CI: 5.3-8.7). 
High level enzyme elevation (at least > 2 -3 
times of normal range) was found only by 3.5 % 
of patients and only one of them discontinued 
treatment permanently. The mean age during 
the treatment period was 46.6±12.7 (18-84) 
years. Most (84.4%) were female, of which 
68.1% had active disease at the last visit dur-
ing the study period. Mean BMI was 27.3±4.7 
(16.4-42) kg /m2 and it was higher in females 
than males (p<0.001). 
Table 1 shows the liver enzyme elevation 
according to gender, coexisting medical prob-
lems and hepatotoxic drug consumption.
Crcl levels in 8.1% of patients (by Cockroft 
-Gault equation ) ranged from 30-60 ml/min/
1.73m2 and four patients had Crcl values<50 
ml/min/1.73m2.
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The time difference between the onset of 
therapy and occurrence of transaminitis was 
22.1±22.0 (0.3-115) months where 75% of 
the abnormal LFT levels occurred prior to 32 
months. 
The duration of treatment and total cumula-
tive dose of MTX was significantly related  to 
transaminitis, in that 45.2% of the patients who 
received >1.5 g MTX had evidence of elevated 
enzymes. 
According to the duration of treatment, 
217/286 (75.9%) of the patients were treated 
for less than five years, 56/286 (19.6%) be-
tween five to ten years and 13/286 (4.6%) 
above ten years. 
After the classification of patients according 
to the duration of treatment, again the cumu-
lative dose was significantly different in those 
with transaminitis in comparison to the others 
(p<0.001). 
The mean monthly MTX dose was 34.5±10.4, 
and 36±11.5 mg/month in groups with and 
without transaminitis, respectively which was 
not significantly different (Table 2), although 
this proportion was significantly higher in pa-
tients who were treated less than five years in 
comparison with other patients (p<0.001). 
Concurrent dose and concurrent cumulative 
dose of MTX at the time of enzyme eleva-
tion were measured as 8.3±4.1 mg weekly and 
753.7±743.4 mg, respectively. This concurrent 
cumulative dose was lower than the total cu-
mulative dose in both groups but again after 
dividing the duration of treatment (35.5±9.1 
mg/mo), there was no difference between this 
proportion and the mean monthly MTX dose, 
as noted earlier. 
After the first enzyme elevation, the MTX 
dose was either reduced or discontinued in 
31.4% of these patients. As a result, normaliza-
tion of liver enzymes were seen among 73.5% 
of the patients after 3.5±2.3 months. MTX 
dose was reduced or discontinued in 33.3% 
of the remainder of high risk patients who had 
two consecutive enzyme elevations with nor-
malization seen with the third enzyme among 
73.3% of these high risk patients. One patient, 
herself, with NASH discontinued MTX treat-
ment after 15 months with normalization in her 
enzymes. 
No evidence of clinical cirrhosis was seen 
until the last visit in the study period.
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Table  1: Enzyme elevation according to gender, coexisting
medical problems and hepatotoxic drug consumption.
   Group with  Group with no- p-value
 hepatotoxicity hepatotoxicity   
           (%)            (%)
Gender (female) 25 16.2 0.89
Liver disease* 50 22.7 0.09
Congestive heart  41.7 22.7 0.16
failure
Alcohol consumption 1.8 0.5 0.42
Cigarette smoking 12.5 24.4 0.38
Diabetes mellitus 30.4 23 0.44
Hypertriglyceridemia 26.8 23 0.69
Hypercholesterolemia 32.3 22.4 0.44
Hepatotoxic drug  31.3 14 0.001
consumption**
Use of chloroquine 22.8 26.9 0.69
  * Autoimmune hepatitis, non-alcoholic steatohepatitis, liver congestion due to con-
gestive heart failure and mitral stenosis, Gilberts’ disease, autoimmune hepatitis 
and liver hemangioma.
** NSAID, Sulfasalazine, Angiotensin Converting Enzyme inhibitors and Angiotensin 
       Receptor Blockers, Statins and Omeprazole. (Prednisolone has been used in all of the 
       patients).
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Table  2:  Risk factor comparison between patients with or 
                    without liver enzyme elevation.
 Patients with     Patients with  p-value
    abnormal  normal LFTs (SD)   
    LFTs (SD)            
Age (years)  46.1 (13.1) 46.4 (12.4) 0.89
BMI (kg/m2)  27.4 (5.1) 46.9 (4.6) 0.55
Crcl  107 (42.3) 103.3 (32.4) 0.45
(cc/min/1.73 m2)
Duration of  59.6 (42.3) 35.6 (31.0) <0.001
treatment with MTX 
(months)
Interval of LFTs 4.5 (2.4) 4.8 (3.3) 0.34
(months)
Total cumulative         1707.3 (1231.1) 1205.7 (1086.9) <0.001
dose of MTX (mg)
Mean MTX dose  34.5 (10.4) 36 (11.5) 0.78
per month (mg/month)
DISCUSSION
This study showed that transaminitis occurred 
among 23.7% of patients who received ≥7.5mg 
MTX per week.
The average duration of treatment among 
patients with transaminitis was significantly 
higher than the other patients and it was noted 
that the cumulative dose of MTX was also sig-
nificantly related to the occurrence of transa-
minitis. 
Yazici et al. estimated the frequency of AST 
elevation above 40 or ALT above 50 by 16.5% 
in their first article.16 In their second paper, the 
incidence of MTX-induced transaminitis was 
reported in a cohort study to be 7.1 per 100 per-
son-years exposure to MTX.17 In comparison 
with our study, the incidence of transaminitis 
was significantly lower. This difference may 
be partially attributed to different intervals of 
enzyme measurements, which were longer in 
our study.16, 17 Additionally, in the second ar-
ticle by Yazici et al., the likelihood of a clini-
cally severe abnormality (including AST value 
above 80) was similar during each year of the 
five years of observation, which contradicted 
the findings of our study where the maximum 
incidence of enzyme elevation occurred during 
the initial years of treatment with MTX.17 
The age of our study population was lower 
than other studies14,15,17; thus the younger age of 
patients in this study may be a reason for mask-
ing the effect of age on transaminitis, probably 
due to better MTX hepatic clearance. 
As with other studies,3,18 in our study the 
BMI was higher among women. In addition, 
transaminitis may be influenced by numerous 
other factors such as younger age and lower 
dose of MTX administration. 
Hydroxychloroquine, as previously noted to 
be a protective factor of MTX-induced transa-
minitis19, was used by the majority of patients 
and might be one of the above factors, how-
ever multivariate analysis did not support this 
hypothesis. 
BMI was higher when compared to the other 
reports3,18  but despite of high BMI among the 
patients in our study, no significant relation 
was found between the risk factors of NASH 
and presence of  transaminitis (such as hyper 
triglyceridemia, diabetes and obesity), against 
to Langman et al.7 study about NASH. 
The limitation of this study was that no liver 
biopsies were performed for determining  the 
real importance of transaminitis.20 However, 
histology-based studies favor the effect of 
MTX on the progression of fibrosis21 and show 
a positive predictive value of 30% for fibro-
sis by serial abnormal liver function tests.15 In 
addition, many trials show the incoherency of 
liver enzymes and histological findings.15, 22 
In conclusion, MTX transaminitis is a com-
mon complication of long-term treatment with 
MTX as based on liver enzyme elevation. 
Transaminitis is associated with mild liver en-
zyme elevation and is related to the duration 
of therapy.
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